 |
|
 |
Abbott Laboratories |
|
|
Abbott Laboratories
Pipeline,Products,Performance,Potential
Publication Date March 2008
Publisher Espicom
Product Type Strategic Report
Pages 142
ISBN Number not applicable
Product Code ESP1005
|
|
|
Summary
Pharmaceutical company intelligence reports from Espicom provide a full review of the company's activities together with five-year sales forecasts for its key products. The company's financial performance is covered in-depth, from its latest results to a complete analysis of its latest full fiscal year and an outlook for the future. A section on company strategy covers mergers, acquisitions and divestitures, key agreements, products and R&D. An overview of key products and R&D is followed by a comprehensive review of the company's product portfolio and research and development pipeline by therapeutic area. In addition, supplementary appendices provide more in-depth information on financials, agreements and corporate events.
|
Content
- Executive Summary
- A detailed and comprehensive overview of current financial position, company strategy, product and pipeline analysis.
- Therapeutic Area Focus
- Key product analysis and forecasting
- Inflammation
- Cardiovascular
- Neuroscience
- Depakote/Epival/Valcote (divalproex sodium)
- Virology
- Kaletra (lopinavir+ritonavir)
- Anti-infectives
- Biaxin/Klacid/Klaricid/Biclar (clarithromycin)
- Omnicef (cefdinir)
- Anaesthetics
- Sevorane/Ultane (sevoflurane)
- Metabolic
- Synthroid (levothyroxine sodium)
- Oncology
- Lupron Depot/Lucrin (leuprolide)
- Gastrointestinal
- Operational Data
- A wealth of background and detail
- A full 5-year financial performance assessment
- Key agreements
- Infrastructure
- Subsidiaries and joint ventures
|
|
|
